ROQ Insider Trading

Insider Ownership Percentage: 70.98%
Insider Buying (Last 12 Months): £32,395.99
Insider Selling (Last 12 Months): GBX 0

Roquefort Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Roquefort Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Roquefort Therapeutics Share Price & Price History

Current Price: GBX 4.75
Price Change: +0.30 (1.20%)
As of 04/19/2024 01:00 AM ET

This chart shows the closing price history over time for ROQ up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Roquefort Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2023Dr Darrin DisleyInsiderBuy269,935GBX 7£18,895.45
7/12/2023Stephen Paul WestInsiderBuy15,730GBX 6£943.80
6/26/2023Stephen Paul WestInsiderBuy144,117GBX 7£10,088.19
6/23/2023Trevor Ajanthan (Ajan) ReginaldInsiderBuy35,265GBX 7£2,468.55
9/26/2022Dr Darrin DisleyInsiderBuy515,913GBX 8£41,273.04
7/4/2022Stephen Paul WestInsiderBuy210,000GBX 9£18,900
6/30/2022Stephen Paul WestInsiderBuy55,147GBX 9£4,963.23
1/19/2022Stephen Paul WestInsiderBuy50,000GBX 10£5,000
See Full Table

SEC Filings (Institutional Ownership Changes) for Roquefort Therapeutics (LON:ROQ)

1.74% of Roquefort Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Roquefort Therapeutics logo
Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action. Roquefort Therapeutics plc was incorporated in 2020 and is based in London, the United Kingdom.
Read More on Roquefort Therapeutics

Today's Range

Now: GBX 4.75
Low: 4.50
High: 4.75

50 Day Range

MA: GBX 6.82
Low: 4
High: 9.25

52 Week Range

Now: GBX 4.75
Low: 3.90
High: 9.50

Volume

329,690 shs

Average Volume

319,000 shs

Market Capitalization

£6.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Roquefort Therapeutics?

Roquefort Therapeutics' top insider investors include:
  1. Dr Darrin Disley (Insider)
  2. Stephen Paul West (Insider)
  3. Trevor Ajanthan (Ajan) Reginald (Insider)
Learn More about top insider investors at Roquefort Therapeutics.